Literature DB >> 27495118

Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry.

Michael G Feasel1, Ariane Wohlfarth2,3,4, John M Nilles5, Shaokun Pang6, Robert L Kristovich7, Marilyn A Huestis2.   

Abstract

Carfentanil is an ultra-potent synthetic opioid. No human carfentanil metabolism data are available. Reportedly, Russian police forces used carfentanil and remifentanil to resolve a hostage situation in Moscow in 2002. This alleged use prompted interest in the pharmacology and toxicology of carfentanil in humans. Our study was conducted to identify human carfentanil metabolites and to assess carfentanil's metabolic clearance, which could contribute to its acute toxicity in humans. We used Simulations Plus's ADMET Predictor™ and Molecular Discovery's MetaSite™ to predict possible metabolite formation. Both programs gave similar results that were generally good but did not capture all metabolites seen in vitro. We incubated carfentanil with human hepatocytes for up to 1 h and analyzed samples on a Sciex 3200 QTRAP mass spectrometer to measure parent compound depletion and extrapolated that to represent intrinsic clearance. Pooled primary human hepatocytes were then incubated with carfentanil up to 6 h and analyzed for metabolite identification on a Sciex 5600+ TripleTOF (QTOF) high-resolution mass spectrometer. MS and MS/MS analyses elucidated the structures of the most abundant metabolites. Twelve metabolites were identified in total. N-Dealkylation and monohydroxylation of the piperidine ring were the dominant metabolic pathways. Two N-oxide metabolites and one glucuronide metabolite were observed. Surprisingly, ester hydrolysis was not a major metabolic pathway for carfentanil. While the human liver microsomal system demonstrated rapid clearance by CYP enzymes, the hepatocyte incubations showed much slower clearance, possibly providing some insight into the long duration of carfentanil's effects.

Entities:  

Keywords:  carfentanil; metabolism; norcarfentanil; opioid

Mesh:

Substances:

Year:  2016        PMID: 27495118     DOI: 10.1208/s12248-016-9963-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  27 in total

1.  Identification of fentanyl, alfentanil, sufentanil, remifentanil and their major metabolites in human urine by liquid chromatography/tandem mass spectrometry for doping control purposes.

Authors:  Mario Thevis; Hans Geyer; Daniel Bahr; Wilhelm Schänzer
Journal:  Eur J Mass Spectrom (Chichester)       Date:  2005       Impact factor: 1.067

2.  Virtual computational chemistry laboratory--design and description.

Authors:  Igor V Tetko; Johann Gasteiger; Roberto Todeschini; Andrea Mauri; David Livingstone; Peter Ertl; Vladimir A Palyulin; Eugene V Radchenko; Nikolay S Zefirov; Alexander S Makarenko; Vsevolod Yu Tanchuk; Volodymyr V Prokopenko
Journal:  J Comput Aided Mol Des       Date:  2005-06       Impact factor: 3.686

3.  Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.

Authors:  D E Feierman; J M Lasker
Journal:  Drug Metab Dispos       Date:  1996-09       Impact factor: 3.922

4.  Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor.

Authors:  G Subramanian; M G Paterlini; P S Portoghese; D M Ferguson
Journal:  J Med Chem       Date:  2000-02-10       Impact factor: 7.446

5.  The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans.

Authors:  T Lavé; S Dupin; C Schmitt; B Valles; G Ubeaud; R C Chou; D Jaeck; P Coassolo
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

6.  Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx).

Authors:  Alexander Cole; Adrian Mutlow; Ramiro Isaza; James W Carpenter; David E Koch; Robert P Hunter; Betsy L Dresser
Journal:  J Zoo Wildl Med       Date:  2006-09       Impact factor: 0.776

7.  Quantitative low-volume assay for simultaneous determination of fentanyl, norfentanyl, and minor metabolites in human plasma and urine by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Authors:  Nina Sophia Mahlke; Victoria Ziesenitz; Gerd Mikus; Gisela Skopp
Journal:  Int J Legal Med       Date:  2014-07-06       Impact factor: 2.686

8.  Metabolism and bioactivation of clozapine by human liver in vitro.

Authors:  M Pirmohamed; D Williams; S Madden; E Templeton; B K Park
Journal:  J Pharmacol Exp Ther       Date:  1995-03       Impact factor: 4.030

9.  Tissue redistribution of fentanyl and termination of its effects in rats.

Authors:  C C Hug; M R Murphy
Journal:  Anesthesiology       Date:  1981-10       Impact factor: 7.892

10.  Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide.

Authors:  J R Cashman; S B Park; Z C Yang; S A Wrighton; P Jacob; N L Benowitz
Journal:  Chem Res Toxicol       Date:  1992 Sep-Oct       Impact factor: 3.739

View more
  15 in total

1.  Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats.

Authors:  Marianne Skov-Skov Bergh; Inger Lise Bogen; Nancy Garibay; Michael H Baumann
Journal:  Neuropharmacology       Date:  2019-04-06       Impact factor: 5.250

2.  Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.

Authors:  Lauren C Smith; Paul T Bremer; Candy S Hwang; Bin Zhou; Beverly Ellis; Mark S Hixon; Kim D Janda
Journal:  J Am Chem Soc       Date:  2019-06-25       Impact factor: 15.419

3.  Synthesis and μ-Opioid Activity of the Primary Metabolites of Carfentanil.

Authors:  Fu-Lian Hsu; Andrew J Walz; James M Myslinski; Li Kong; Michael G Feasel; Tyler D P Goralski; Tim Rose; Nicholas J Cooper; Neil Roughley; Christopher M Timperley
Journal:  ACS Med Chem Lett       Date:  2019-10-16       Impact factor: 4.345

4.  Case report: relevance of metabolite identification to detect new synthetic opioid intoxications illustrated by U-47700.

Authors:  Camille Richeval; Jean-Michel Gaulier; Ludovic Romeuf; Delphine Allorge; Yvan Gaillard
Journal:  Int J Legal Med       Date:  2018-11-15       Impact factor: 2.686

5.  In Vitro and In Vivo Metabolite Identification Studies for the New Synthetic Opioids Acetylfentanyl, Acrylfentanyl, Furanylfentanyl, and 4-Fluoro-Isobutyrylfentanyl.

Authors:  Shimpei Watanabe; Svante Vikingsson; Markus Roman; Henrik Green; Robert Kronstrand; Ariane Wohlfarth
Journal:  AAPS J       Date:  2017-04-05       Impact factor: 4.009

Review 6.  Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.

Authors:  Randy Torralva; Aaron Janowsky
Journal:  J Pharmacol Exp Ther       Date:  2019-09-06       Impact factor: 4.030

7.  Carfentanil and Current Opioid Trends in Summit County, Ohio.

Authors:  Kristy Waite; Amy Deeken; Steve Perch; Lisa J Kohler
Journal:  Acad Forensic Pathol       Date:  2017-12-01

Review 8.  Fentanyls continue to replace heroin in the drug arena: the cases of ocfentanil and carfentanil.

Authors:  Nektaria Misailidi; Ioannis Papoutsis; Panagiota Nikolaou; Artemisia Dona; Chara Spiliopoulou; Sotiris Athanaselis
Journal:  Forensic Toxicol       Date:  2017-08-18       Impact factor: 4.096

9.  Human deaths from drug overdoses with carfentanyl involvement-new rising problem in forensic medicine: A STROBE-compliant retrospective study.

Authors:  Dmitrij Fomin; Vilma Baranauskaite; Emilija Usaviciene; Alina Sumkovskaja; Sigitas Laima; Algimantas Jasulaitis; Zita Nijole Minkuviene; Sigitas Chmieliauskas; Jurgita Stasiuniene
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

Review 10.  Drug Interactions With New Synthetic Opioids.

Authors:  Clara Pérez-Mañá; Esther Papaseit; Francina Fonseca; Adriana Farré; Marta Torrens; Magi Farré
Journal:  Front Pharmacol       Date:  2018-10-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.